EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice

Yaru Quan, Shiqiang Luo, Shuang Wu, Kaiqin Wang, Lixing Hu, Yihuan Hao, Kangwei Xu, Yong Liu

Viruses · 2025

DOI: 10.3390/v18010053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Yaru Quan und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Regulatory Science (SKLDRS), National Institutes for Food and Drug Control, Beijing 102629, China. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Herpes Zoster, Viral Envelope Proteins, Herpesvirus 3, Human. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Varicella-zoster virus (VZV) is a human neurotropic herpesvirus. The primary infection with VZV causes chickenpox and establishes latency in sensory and dorsal root ganglia. Viral reactivation leads to herpes zoster (HZ), which is accompanied by complications such as postherpetic neuralgia (PHN), causing a significant disease burden. At present, vaccination is the most effective preventive measure. We developed a recombinant zoster vaccine, gE/BFA01, which comprises truncated VZV glycoprotein E and the liposome-based adjuvant BFA01 (containing MPL and QS-21). In this study, we evaluated the recombinant zoster vaccine’s immunogenicity in a live attenuated VZV-primed C57BL/6N mouse model and explored the mechanism of action of the BFA01 adjuvant. The results indicate that the gE/BFA01 vaccine induces superior antibody responses and stronger cellular immune responses compared with gE with aluminum hydroxide. Furthermore, gE/BFA01 showed comparable immunogenicity to the licensed vaccine Shingrix. Mechanistic investigations revealed that the BFA01 adjuvant can enhance the recruitment of innate immune cells at the injection site, increase the expression of DCs surface maturation markers, and activate multiple inflammatory signaling pathways in lymph nodes. Collectively, these findings indicate that gE/BFA01 can induce potent humoral and cellular responses, supporting its further development as a high-efficiency vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes Zoster VaccineHerpes ZosterViral Envelope ProteinsHerpesvirus 3, HumanImmunogenicity, VaccineAnimalsMiceAntibodies, ViralMice, Inbred C57BLAdjuvants, ImmunologicVaccines, SyntheticFemaleImmunity, CellularAdjuvants, VaccineHumans

Stichwörter der Autor:innen

cellular immune responseshumoral immune responsesnovel adjuvantrecombinant zoster vaccinevaricella zoster virus

Substanzen

Herpes Zoster VaccineAntibodies, ViralAdjuvants, ImmunologicVaccines, SyntheticViral Envelope Proteinsglycoprotein E, varicella-zoster virusAdjuvants, Vaccine

Autor:innen und Institutionen

  • State Key Laboratory of Drug Regulatory Science (SKLDRS), National Institutes for Food and Drug Control, Beijing 102629, China.
  • Beijing ABZYMO Biotechnology Co., Ltd., Beijing 100176, China.
  • Jiangsu Recbio Technology Co., Ltd., Taizhou 225316, China.

Zitieren

APA

Quan, Y., Luo, S., Wu, S., Wang, K., Hu, L., Hao, Y., Xu, K., & Liu, Y. (2025). Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice. Viruses. https://doi.org/10.3390/v18010053

Vancouver

Quan Y, Luo S, Wu S, Wang K, Hu L, Hao Y, et al. Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice. Viruses. 2025. doi:10.3390/v18010053

BibTeX
@article{Quan2025,
  author = {Quan, Yaru and Luo, Shiqiang and Wu, Shuang and Wang, Kaiqin and Hu, Lixing and Hao, Yihuan and Xu, Kangwei and Liu, Yong},
  title = {Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v18010053}
}
Kostenlos starten →